(AROAF)
- Previous Close
0.0000 - Open
-- - Bid 0.2439 x --
- Ask --
- Day's Range
-- - 52 Week Range
0.2439 - 0.4000 - Volume
-- - Avg. Volume
3,716 - Market Cap (intraday)
89.23M - Beta (5Y Monthly) 0.49
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; Myriad Morcells, a morcellized (powdered) format of Myriad Matrix for soft tissue repair and complex wounds; Myriad Morcells Fine that delivers a bolus of biologically important ECM proteins to help kick start and sustain healing; and OviTex and OviTex PRS, a reinforced bioscaffolds for use in hernia repair and abdominal wall reconstruction, as well as breast reconstruction. The company also offers Symphony, a combination cellular and tissue product, indicated for the regeneration of functional tissue in complex wounds. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
aroa.comRecent News: AROAF
View MorePerformance Overview: AROAF
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AROAF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AROAF
View MoreValuation Measures
Market Cap
89.23M
Enterprise Value
80.45M
Trailing P/E
--
Forward P/E
59.52
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.88
Price/Book (mrq)
1.57
Enterprise Value/Revenue
1.80
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-9.98%
Return on Assets (ttm)
-5.67%
Return on Equity (ttm)
-8.05%
Revenue (ttm)
76.35M
Net Income Avi to Common (ttm)
-7.62M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
21.9M
Total Debt/Equity (mrq)
7.48%
Levered Free Cash Flow (ttm)
-10.59M